ASH 2018 | IDH inhibitors for AML: highlights from ASH 2018

Marina Konopleva

Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an update on the key news for IDH1/2 inhibitors for acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video